Embargoed Until November 1 @ 2PM EDT
Contact: Rachel Zuckerman
Mount Sinai Press Office
(646) 605-7693
[email protected]
Diabetes Medications May Reduce Alzheimer’s Disease Severity,
Mount Sinai Researchers Report
Networks identified for developing new therapies
Newswise — NEW York, NY (November 1) People with Alzheimer’s disease who were treated with diabetes drugs showed considerably fewer markers of the diseaseincluding abnormal microvasculature and disregulated gene expressionsin their brains compared to Alzheimer’s patients without treatment for diabetes, Mount Sinai researchers report.
Results of the study will be published in PLOS One online on November 1st at 2PM.
This is the first study to examine what happens in the pathways of both brain tissue and endothelial cells—the cells lining blood vessels—in the brains of Alzheimer’s patients treated with diabetes medication. The results of the study will inform future Alzheimer’s disease studies and potential new therapies targeting specific cells, since they suggest that targeting the brain’s capillary system could have beneficial effects in Alzheimer’s patients.
Many elderly people with diabetes have brain changes that are hallmarks of Alzheimer’s. Despite this linkage, two previous Mount Sinai studies on brain tissue found that the brains of people with both Alzheimer’s disease and diabetes had fewer Alzheimer’s lesions than the brains from people with Alzheimer’s disease without diabetes. The results suggested that anti-diabetes medications had a protective effect on the brains of Alzheimer’s disease patients.
To determine what happens at the molecular level, this Mount Sinai research team developed a method to separate brain capillaries from the brain tissue of 34 people with Alzheimer’s and type 2 diabetes who had been treated with anti-diabetes drugs and compare them to tissue from 30 brains of people with Alzheimer’s without diabetes and 19 brains of people without Alzheimer’s or diabetes. (Because most people who have diabetes are treated with insulin or oral medications, the scientists were unable to compare their results to brain tissue from people with Alzheimer’s disease and diabetes who were not treated with anti-diabetes drugs.)
Then, they examined the vessels and brain tissue separately to measure Alzheimer’s Disease associated changes in molecular RNA markers for brain capillary cells and insulin signaling.
The levels of about half of these markers were reduced in the vessels and brain tissue in the group with Alzheimer’s and diabetes. The great majority of the RNA changes seen in Alzheimer’s disease were absent in those Alzheimer’s patients who had been treated with anti-diabetes drugs.
“The results of this study are important because they give us new insights for the treatment of Alzheimer’s disease,” said the study’s senior author, Vahram Haroutunian, PhD, Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai.
“Most modern Alzheimer’s treatments target amyloid plaques and haven’t succeeded in effectively treating the disease,” said Dr. Haroutunian. “Insulin and diabetes medications such as metformin are FDA approved and safely administered to millions of people and appear to have a beneficial effect on people with Alzheimer’s. This opens opportunities to conduct research trials on people using similar drugs or on drugs that have similar effects on the brains’ biological pathways and cell types identified in this study.”
Other Mount Sinai authors of the paper include Sam Gandy, MD, PhD, Associate Director of the Alzheimer's Disease Research Center at Mount Sinai; Michal Schnaider-Beeri, PhD, Professor of Psychiatry; Pavel Katsel, PhD, Associate Professor of Psychiatry; Miguel Gama-Sosa, PhD, Associate Professor of Psychiatry; and Sonia Khan, associate researcher.
The Mount Sinai research team plans to study these drugs and their molecular pathways in greater detail using a combination of postmortem human brain cells and mouse models.
This study was supported by grants from the U.S. Department of Veterans Affairs and the National Institutes of Health.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 7,100 primary and specialty care physicians; 10 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report’s “Honor Roll” of top U.S. hospitals; it is one of the nation’s top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in four other specialties in the 2017-2018 “Best Hospitals” issue. Mount Sinai’s Kravis Children’s Hospital also is ranked in six out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.
RSS